



4 August 2025

Sydney, Australia

## Nyrada Successfully Raises \$8.25 Million via Placement

### Highlights:

- Nyrada has successfully raised \$8.25 million of new equity capital (before costs) by way of a placement to new and existing institutional, sophisticated and professional investors.
- Placement follows recent announcement of Nyrada's Phase IIa clinical trial planning to assess the safety and efficacy of Xolatryp in patients with acute myocardial infarction.
- Nyrada is now fully funded to complete a Phase IIa clinical trial in cardioprotection, drug manufacture and formulation, and low-cost studies into other indications.

**Nyrada Inc (ASX:NYR)**, a clinical stage drug discovery and development company focused on advancing treatments across a portfolio of indications through innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibition, today announces that it has received firm commitments for a placement of 27.5 million Chess Depositary Instruments (CDIs), raising \$8.25 million in new equity capital from new and existing institutional, professional and sophisticated investors (Placement).

The Placement issue price was \$0.300 per CDI, representing a 18.9% discount to the last traded price (\$0.370) and a 5.0% discount to the 15-day volume weighted average price (VWAP) of Nyrada's CDIs (\$0.315).

The Placement follows Nyrada's recent announcement of its planned Phase IIa clinical trial to assess the safety and efficacy of Xolatryp™ in patients with acute myocardial infarction.

Nyrada's Phase I trial of Xolatryp is nearing completion, which when combined with strong preclinical evidence for cardioprotection in an infarct model, has provided the Company with confidence to commit to a Phase IIa clinical trial for this therapeutic indication.

**Nyrada CEO, James Bonnar commented:** "We are very pleased and deeply grateful for the strong interest and continued support from CDI holders. We warmly welcome new investors and look forward to keeping the market updated as we advance.

"Over the past 18 months, Nyrada has made significant strides toward the commercialisation of Xolatryp. In addition to multiple successful pre-clinical studies, we have successfully completed Good Laboratory Practice (GLP) studies and the dosing phase of our Phase I trial.



“Looking ahead, the next 12 to 18 months promise to be equally, if not more, transformative. By this time next year, we expect to be well advanced in our Phase IIa study—a critical milestone on our path forward. This is an exciting and pivotal period for Nyrada, and we remain focused on delivering economic and therapeutic value as we continue to progress.”

**Nyrada Chair, John Moore commented:** “Thank you to all CDI holders, existing and incoming, for your support. This is a very exciting time to be a Nyrada holder as we advance towards a Phase IIa clinical trial. We are now well capitalised to progress the development of our first-in-class, multi-target small molecule therapy.

“I take this opportunity to also thank the Nyrada team for their efforts this year during a busy period and one of substantial progress for the Company. Thanks also to the Canary Capital team for their ongoing support to the Company.”

#### Use of Placement Proceeds:

The Company will use the proceeds of the Placement for the following strategic tasks:

Item	Use of Funds
Conduct Phase IIa trial to assess safety and efficacy of Xolatrip	\$7.00m
Development of a non-infusion formulation of Xolatrip	\$0.30m
GMP (Good Manufacturing Practice) manufacture of Xolatrip	\$0.30m
Further research of Xolatrip in other potential indications	\$0.25m
Capital Raising Costs <sup>1</sup>	\$0.40m
Total	\$8.25m

This new capital, coupled with anticipated R&D tax rebates and options exercise proceeds is expected to provide Nyrada with sufficient capital to complete the above strategic tasks.

#### Director and Management Participation

Nyrada Directors and Management have agreed to subscribe in the placement in the amount of \$0.1 million on the same terms as the Placement CDIs. Director participation is subject to CDI holder approval at the Company’s Annual General Meeting (AGM) scheduled for November 2025. Director and Management CDIs are included in the total number of CDIs (27.5 million CDIs) to be issued as part of this capital raise.

A formal Notice of Meeting confirming the date of the AGM will be issued in due course.

<sup>1</sup> Canary Capital has agreed to accept \$0.13 million of its fees by way of 433,333 CDIs.



[Canary Capital Pty. Limited](#) (**Canary**) acted as lead manager to the capital raise. As lead manager, Canary is entitled to a fee of 6% (exclusive of GST) of the total amount raised. Canary has agreed to accept \$0.13 million of its fees by way of 433,333 CDIs. These CDIs are included in the total number of CDIs (27.5 million CDIs) to be issued as part of this capital raise. Additionally, Canary will receive 7.3 million unlisted options over CDIs. The exercise price for these broker options is \$0.45 and the exercise period will expire on 11 August 2027 (**Broker Options**).

**Paul Hart, Executive Director of Canary Capital commented:** “We are very pleased with Nyrada’s achievements since the last capital raise was completed. The Company has successfully progressed Xolatryp through animal and Phase I human safety trials, and Canary Capital is equally enthusiastic about the planned Phase IIa trial for Xolatryp.”

This Placement and the broker options are being issued under the Company’s available placement capacity under ASX Listing Rules 7.1 and 7.1a.

The expected settlement and CDI issue date for the placement will occur over two tranches in August 2025 per the following indicative table.

**Indicative Placement Timetable:**

Event	Date
Trading Halt Lifted	Monday 4 August 2025 (before 10am AEST)
Tranche 1 Settlement Date	Friday 8 August 2025
Tranche 1 Issue of 26,500,000 CDIs	Monday 11 August 2025
Issue of 7,300,000 Broker Options	Monday 11 August 2025
Tranche 2 Settlement Date	Tuesday 19 August 2025
Tranche 2 Issue of 1,000,000 CDIs	Wednesday 20 August 2025
Annual General Meeting	Wednesday 12 November
Director Placement Settlement Date	Friday 21 November 2025
Director Placement Issue of 300,000 CDIs	Friday 28 November 2025

*This timetable is indicative only and Nyrada may, at its absolute discretion, vary any of the above dates, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth) and other applicable laws.*

-ENDS-



### About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both neuroprotection and cardioprotection, and is nearing completion of its first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.*

### Investors and Media:

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.